The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Treatment strategies for patients with DLBCL who relapse after CAR-T therapy
Despite the success of CAR-T therapy in the ZUMA-7 (NCT03391466) and TRANSFORM trials (NCT03575351), there is no standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CAR-T therapy. Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses various strategies including radiotherapy in cases of localized relapse, salvage chemotherapy, and bispecific antibodies such as epcoritamab and glofitamab. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
